# Zhihua Xiao

> Zhihua Xiao is the founder, chairman and CEO of OPM Biosciences, a scientist-operator who turned a career in mammalian cell culture into a company built around cell culture media and biologics development services. After earning a Ph.D. at the University at Buffalo and working at Life Technologies and ChemPartner, he founded OPM in Shanghai in 2013. The company later listed on the Shanghai Stock Exchange, established a US presence in Pleasanton, California, and expanded from media into end-to-end development and manufacturing services.

- **Role:** Founder, Chairman and CEO at OPM Biosciences
- **Organizations:** OPM Biosciences, Life Technologies Corporation, ChemPartner, University at Buffalo
- **Nationality:** Chinese
- **Education:** Ph.D.; dissertation: Platelet-Neutrophil Adhesion and Neutrophil Activation Induced by Platelet Activation, University at Buffalo, The State University of New York
- **Known for:** Founded OPM Biosciences in 2013 and led it to a 2022 listing on the Shanghai Stock Exchange STAR Market., Built a business combining cell culture media with end-to-end biologics development and manufacturing services., Expanded OPM internationally with laboratories and offices in the United States.

## Career timeline

- **2000-2007** — Completed doctoral research at the University at Buffalo on platelet-neutrophil adhesion and neutrophil activation.
- **2007-2013** — Worked at Life Technologies Corporation, advancing from scientist to Senior R&D Manager and Process Science Fellow.
- **2013** — Served as Senior Director of Biologics at ChemPartner, overseeing CMC work from cell-line development through pilot manufacturing.
- **2013** — Returned to China and founded Shanghai OPM Biosciences around cell culture media and bioprocess development.
- **2022-04** — OPM established a US subsidiary in the San Francisco Bay Area to support international customers.
- **2022-09** — OPM Biosciences listed on the Shanghai Stock Exchange STAR Market under ticker 688293.
- **2024-03** — Presented on reducing biomanufacturing costs with next-generation CHO media at the American Chemical Society spring meeting in New Orleans.
- **2025** — Joined the Shanghai Stock Exchange Global Investors Conference panel on cultivating world-class pharmaceutical companies.
- **2026-04** — Presented OPM's 2025 operating results at the company's annual investor conference call as chairman and general manager.

## Achievements

- Founded OPM Biosciences in 2013 and led it to a 2022 listing on the Shanghai Stock Exchange STAR Market.
- Built a business combining cell culture media with end-to-end biologics development and manufacturing services.
- Expanded OPM internationally with laboratories and offices in the United States.
- Developed more than 25 years of experience in mammalian cell culture and therapeutic drug development.
- Led OPM's expansion to two cell culture media manufacturing sites and biologics development and manufacturing centers.

## Latest updates

- **2026-04** — Xiao led OPM's 2025 annual results call; the company said it was continuing its integrated cell culture products plus biologics development and manufacturing strategy.
- **2025-12** — Chinese regulators approved registration of OPM's proposed acquisition of PharmaLegacy, extending the company's planned model from media plus CDMO toward a broader CRDMO platform.
- **2025-11** — Xiao appeared at the Shanghai Stock Exchange Global Investors Conference on a panel about building world-class pharmaceutical companies.
- **2025-09** — Xiao highlighted OPM's first BioProcess International appearance in Boston and the company's next-generation CHO media work.

## Links

- Website: https://opmbio.com
- LinkedIn: https://www.linkedin.com/in/zhihua-xiao-7931626

---

Profile page: https://yespress.io/zhihua-xiao
Published by YesPress — https://yespress.io
Last updated: 2026-09-27